AiMOGA Robotics, a brand under Chery, introduced Mobo, its first consumer-grade humanoid robot designed as a family companion, at the 2026 Chery International User Summit. Mobo operates with AiMOGA's proprietary MoAgent AI, enabling it to understand complex commands, recognize objects, and interact naturally within home environments. The robot can remember family members' habits, perform expressive gestures, and ensure privacy protection. This launch marks AiMOGA's expansion from commercial services into the consumer market, with global pre-orders now open. The event also showcased AiMOGA's diverse robot ecosystem applied across public service, retail, and healthcare sectors.
AiMOGA's launch of the Mobo family companion robot offers context for technology sector trends. For readers following this sector, here is Pluang's market snapshot as of Oct 17, 2026 20:02 WIB: out of 150 technology stocks, only 11 rose while 139 fell. Notable movers include Twilio Inc (TWLO) at USD 244.37 with a 10.62% decline and a typical hold time of 56 days on Pluang.
Chery Auto will showcase its purpose-built Level 4 (L4) Robotaxi at the 2026 Chery International User Summit and sign a strategic cooperation agreement with UAE-based K2. The Robotaxi offers a fully driverless passenger experience from booking to rid...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer-grade humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Powered by AiMOGA's proprietary AI system MoAgent, Mobo can interpret complex command...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Mobo uses advanced AI to understand complex commands, navigate home environments, and remem...
AiMOGA Robotics, a Chery brand, will debut Mobo, its first consumer-grade humanoid robot designed as a home companion, at the 2026 Chery International User Summit in Wuhu, China. Mobo features advanced AI for understanding complex commands, spatial a...
Ascendis Pharma announced that the European Medicines Agency's CHMP has issued a positive opinion recommending approval of TransCon CNP (navepegritide), a once-weekly treatment for achondroplasia in children aged two and older with open growth plates...
